Sahlgrenska University Hospital
Gothenburg, 413 45, Sweden
NCT Number: NCT04460053
A prospective feasibility trial initially including 10 patients to investigate if Neurofilament light protein can be detected in peripheral blood in patients undergoing Isolated Limb Perfusion with chemotherapeutic agents. This biomarker could act as predictive biomarker for neurotoxicity after isolated limb perfusion.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Gothenburg, 413 45, Sweden
In isolated limb perfusion (ILP) neurotoxicity is a known side effect, this is in spite of the fact that a relatively mild hyperthermic temperature is used which should be well tolerated by the nerves and other normal tissues in the limbs. It seems probable that the neurotoxicity observed after ILP results from both a thermal enhancement of drug toxicity combined with a local effect of a high tourniquet pressure that is used to isolate the blood flow. Prevention of regional and systemic toxicity is essential for improving the outcome after the procedure. It is known that both higher doses of melphalan, higher temperatures and longer perfusion time correlates to a higher toxicity. The Wieberdink method is a grading system for the reaction of the normal tissues after ILP and the grading is used as a routine in ILP today. Neurofilament light protein (NfL) is released into the cerebrospinal fluid (CSF) during axonal damage and has been shown to be elevated in different forms of dementia. An NfL assay sensitive enough to measure NfL in blood was recently developed. Its concentration reflects axonal injury in both central and peripheral nervous system disorders.The primary aim of this study is to investigate the possibility to measure neurofilament as a biomarker for peripheral nerve toxicity after isolated limb perfusion.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A prospective feasibility trial measuring neurofilament light protein in peripheral blood as a biomarker for neurotoxicity after isolated limb perfusion.
Time frame: 1 day postoperatively
Neurofilament light protein
Time frame: 3 days postoperatively
Neurofilament light protein
Time frame: 4 weeks postoperatively
Neurofilament light protein
Vastra Gotaland Region
Other Gov
A Prospective Feasibility Trial Measuring Neurofilament Light Protein in Peripheral Blood as a Biomarker for Neurotoxicity After Isolated Limb Perfusion.
Acronym: ILP-NfL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03236935
Bronchial Neoplasms, Carcinoma
Houston, Texas, United States
View Trial DetailsNCT07427953
Drug-Induced Retinopathy, Malignant Melanoma
Ljubljana, Slovenia
View Trial DetailsNCT07436390
Malignant Melanoma, Melanoma
Ljubljana, Slovenia
View Trial DetailsNCT07431489
MEK Inhibitor-Associated Retinopathy, Malignant Melanoma
Ljubljana, Slovenia
View Trial Details